Physicians' Academy for Cardiovascular Education

AHA 2018

PACE-CME.org was present at AHA Scientific Sessions 2018 in Chicago, IL. Find coverage of the latest CV news on PACE-CME.

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

Physical activity: every step counts, for everybody

3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA

Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort

3' education - Nov. 15, 2018 - JoAnn Manson, MD

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients

3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD

Not all fish oils are created equal: different compounds have different effects

3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

Comprehensive US approach to stimulate physical activity should tackle obesity and improve health

3' education - Nov. 13, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Highly purified EPA reduces important ischemic events in hypertriglyceridemia

3' education - Nov. 11, 2018 - Deepak Bhatt, MD - Boston, MA, USA.

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

AHA 2018 - Chicago, IL, USA

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD
Treatment with icosapent ethyl yielded a strong reduction in CV events in statin-treated patients at high CV risk and residual TG burden. Prof. Stroes considers what we can conclude about how this benefit is achieved.

AHA 2018 Treatment with icosapent ethyl yielded a strong reduction in CV events in statin-treated patients at high CV risk and residual TG burden. Prof. Stroes considers what we can conclude about how this benefit is achieved.

Lowering Lp(a) potently and safely with antisense technology

AHA 2018 - Chicago, IL, USA

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD
Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

AHA 2018 Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

Physical activity: every step counts, for everybody

AHA 2018 - Chicago, IL, USA

3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA
Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.

AHA 2018 Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.

Possibly greater reduction in MACE after patient selection for extended DAPT

News - Nov. 19, 2018

AHA 2018 In PEGASUS-TIMI 54, a patient selection strategy identified a subgroup of patients who may benefit more from long-term treatment with ticagrelor and aspirin, with lower bleeding risk.

SGLT2 inhibitor may promote early reverse cardiac remodeling in T2DM with stable CAD

AHA 2018 – Chicago, IL, USA

News - Nov. 19, 2018

AHA 2018 In the EMPA-HEART Cardiolink-6 trial, 6 months of treatment with empagliflozin reduced LV mass, which may contribute to CV benefits seen in SGLT2i outcome trials.

Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort

AHA 2018 - Chicago, IL, USA

3' education - Nov. 15, 2018 - JoAnn Manson, MD
VITAL evaluated both vitamin D and omega-3 supplementation and found no significant effect on the primary cancer and CV endpoints. Secundary analyses suggested fewer total MI with omega-3 supplementation.

AHA 2018 VITAL evaluated both vitamin D and omega-3 supplementation and found no significant effect on the primary cancer and CV endpoints. Secundary analyses suggested fewer total MI with omega-3 supplementation.

Practice-changing results on in-hospital treatment of acute decompensated HF

AHA 2018 - Chicago, IL, USA

3' education - Nov. 15, 2018 - Larry Allen, MD
Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.

AHA 2018 Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.

Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients

AHA 2018 - Chicago, IL, USA

3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD
Yoga-CaRe as replacement for cardiac rehabilitation did not significantly improve CV endpoints in a large randomized trial, but did improve QoL and return to pre-infarct daily activities.

AHA 2018 Yoga-CaRe as replacement for cardiac rehabilitation did not improve CV endpoints in a large randomized trial, but did improve QoL and return to pre-infarct daily activities.

Not all fish oils are created equal: different compounds have different effects

AHA 2018 – Chicago, IL, USA

3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.
Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

Initiation of ARNI in patients with acute decompensated heart failure

AHA 2018 - Chicago, IL, USA

3' education - Nov. 13, 2018 - Eric Velazquez, MD
Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

Comprehensive US approach to stimulate physical activity should tackle obesity and improve health

AHA 2018 - Chicago, IL, USA

3' education - Nov. 13, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA
U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.

AHA 2018 U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.

Reduced all-cause mortality with PCSK9 inhibitor in patients with ACS

AHA 2018 – Chicago, IL, VS

News - Nov. 12, 2018

AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.

AHA 2018